Aktis Oncology, Inc. (AKTS) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-30

How it makes money

It has no approved products and generates no product sales, relying instead on equity financings and collaboration payments from partners like Eli Lilly.

As a clinical-stage biotechnology company, it does not sell commercial products and has incurred net losses of $63.7 million and $44.0 million for the years ended December 31, 2025 and 2024, respectively. Operations are funded through capital raises, such as an initial public offering that raised net proceeds of $335.3 million, alongside upfront and milestone payments from strategic collaborations.

What protects it: the moat

It relies on management's claims of proprietary miniprotein radioconjugate technology and patent portfolios to protect its unapproved drug candidates from future competition.

The company asserts leadership through its proprietary platform designed to deliver radioisotopes to new tumor targets. However, because its products remain in clinical development without commercial approvals, the true durability of these technological defenses remains unproven against established pharmaceutical competitors.

What growth costs

It must heavily reinvest cash into research and development, clinical trials, and manufacturing scale-up while accumulating substantial operating losses.

With an accumulated deficit of $156.6 million as of December 31, 2025, the company continually spends capital to advance lead candidates like [225Ac]Ac-AKY-1189 through clinical phases. Maintaining operations requires ongoing expenditures for preclinical studies, regulatory filings, and expanding internal and third-party manufacturing capabilities.

What could damage it

Clinical trial failures or severe adverse safety events would halt drug development, destroying the scientific premise of its unproven technology platform.

If its lead candidate [225Ac]Ac-AKY-1189 fails to demonstrate safety or efficacy in clinical trials, the company cannot commercialize any products or recover its substantial R&D investments, leading to permanent impairment of its business prospects.

About Aktis Oncology, Inc.

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Other companies in Biotechnology